Neurologix Completes All Surgical Procedures In Its Clinical Trial For Parkinson's Disease
Medical News Today; 10 Dec 2009
http://www.medicalnewstoday.com/articles/173596.php
Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced the completion of all planned surgeries in an ongoing Phase 2 clinical trial of the company's gene transfer approach to the treatment of advanced Parkinson's disease. The controlled, double blinded, 44 patient Phase 2 trial is investigating the safety and efficacy of a novel non-dopamine approach to restore motor function in Parkinson's patients who are sub-optimally responsive to available drug therapy. The company expects to announce initial efficacy results from the trial in mid-2010.
The investigators are assessing each of the trial participants over time for treatment effects, with the primary trial endpoint being a clinical assessment of motor function at 6 months using the Unified Parkinson's Disease Rating Scale (UPDRS). All participants in the trial will also be monitored for safety for 12 months following their gene transfer procedure.